Inhibition of CSF-1R supports T-cell mediated melanoma therapy

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Sluijter, Marjolein ^a   Van Der Sluis, Tetje C ^a   Van Der Velden, Pieter A ^a   Versluis, Mieke ^a   West, Brian L ^b   Van Der Burg, Sjoerd H ^a   Van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; GAMMA INTERFERON; PLX 3397; UNCLASSIFIED DRUG; CD8 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; INTERFERON PRODUCTION; MACROPHAGE; MELANOMA; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MELANOMA, EXPERIMENTAL; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD8; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MACROPHAGES; MALE; MELANOMA, EXPERIMENTAL; MICE; PROTEIN KINASE INHIBITORS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; T-LYMPHOCYTES;

EID: 84905843059     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104230     Document Type: Article

References (22)

1. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012) Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253-268.
2. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237.
3. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.
4. Hume DA, MacDonald KP (2012) Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119: 1810-1820.
5. Gordon S, Martinez FO (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32: 593-604.
6. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, et al. (2010) Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 70: 8339-8346.
7. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffel B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67.
8. Mok S, Koya RC, Tsui C, Xu J, Robert L, et al. (2014) Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Res 74: 153-161.
9. Ly LV, Sluijter M, van der Burg SH, Jager MJ, van Hall T (2013) Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. J Immunol 190: 489-496.
10. Ly LV, Baghat A, Versluis M, Jordanova ES, Luyten GP, et al. (2010) In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 185: 3481-3488.
11. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, et al. (2013) Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 153: 362-375.
12. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964. (Pubitemid 41746764)
13. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
14. Nagaraj S, Youn JI, Gabrilovich DI (2013) Reciprocal relationship between myeloid-derived suppressor cells and T cells. J Immunol 191: 17-23.
15. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, et al. (2011) M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol 187: 1157-1165.
16. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848. (Pubitemid 44631652)
17. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166. (Pubitemid 46718400)
18. Fend L, Accart N, Kintz J, Cochin S, Reymann C, et al. (2013) Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts. PLoS One 8: e73310.
19. Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, et al. (2009) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther 8: 3151-3161.
20. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, et al. (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19: 1264-1272.
21. Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, et al. (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2: e26968.
22. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, et al. (2013) Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One 8: e54302.